Esco Aster, a vertically integrated cell and derivatives CRDMO based in Singapore, announced on Monday that it will provider CMC manufacturing support for Taiwan-based Shine-On Biomedical's HLA-G targeted exosome program.
Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster's cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On's Investigational New Drug (IND) submission to the US Food and Drug Administration (FDA), and the IND was cleared by the FDA in the first quarter of 2025.
Esco Aster is also providing technical services for exploratory exosome loading feasibility studies based on Shine-On's instruction.
ShineOn's proprietary product, SOB100, is a potential first-in-class HLA-G targeted exosome platform for drug development.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval